Indian Study Finds Vildagliptin SR Effective and Safe in Type 2 Diabetes Patients Uncontrolled on Metformin: PRIME-Vilda Trial
Vildagliptin SR 100 mg once daily has been shown to be effective and safe in improving glycemic control in Indian T2DM patients in India not adequately managed with metformin alone, while offering the advantage of reduced dosing frequency, as demonstrated in the recent PRIME-Vilda trial.
The study was published in the May 2025 issue of Medical Research Archives- the Journal of the European Society of Medicine.
Figure 1: Mean Change in HbA1c (%), Fasting Blood Glucose (FBG) (mg/dL) and Postprandial Blood Glucose (PPBG) (mg/dL) with Vildagliptin(T) vs Sitagliptin(R) from Baseline to Visit 5
Safety:
- No treatment-related or emergent adverse events were reported, and no significant changes were observed in physical examination, vitals, laboratory parameters and ECG. No hypoglycemia episodes requiring assistance occurred in either group (Vildagliptin or Sitagliptin).
Renal & Hepatic Function Parameters:
- Renal function remained stable in both groups (Vildagliptin vs Sitagliptin), with minor changes in serum creatinine (–0.02 mg/dL), uric acid (–0.18 vs +0.10 mg/dL), and urea levels (–2.27 vs –1.31 mg/dL).
- Estimated glomerular filtration rate (eGFR) showed a slight increase in Vildagliptin and a slight decrease in Sitagliptin (+5.85 vs –0.90 mL/min/1.73 m²), indicating preserved renal function.
- Within hepatic parameters, bilirubin levels (total, direct, and indirect) showed minimal changes, with only a slight decrease in direct bilirubin (mean difference: –0.01 g/dL). Liver enzymes (AST, ALT, ALP) remained within normal limits with a slight reduction in ALP (mean difference, Test: -5.31 U/L, Reference: -16.30 U/L)
Lipid & Heart Assessment:
- Total cholesterol remained stable with Vildagliptin (+0.28 mg/dL) and slightly declined with Sitagliptin (−3.81 mg/dL); both groups showed marked reductions in triglycerides (−23.33 mg/dl and −25.13 mg/dL, respectively).
- HDL increased modestly (Vildagliptin: +1.04; Sitagliptin: +0.48 mg/dL), LDL decreased slightly (−2.27 and −2.31 mg/dL), and VLDL levels showed minimal change in both groups (-1.16 mg/dL and -0.07 mg/dL).
- Baseline ECG abnormalities such as sinus bradycardia, left axis deviation (LAD), left ventricular hypertrophy (LVH), T-wave changes, ST-T changes, and left anterior fascicular block (LAFB) were noted but regarded non-significant. By the end of treatment, a considerable number of participants showed favourable improvements in ECG.
Vildagliptin 100 mg SR once daily demonstrated effective glycemic control, good tolerability, and a favorable safety profile in patients with Type 2 diabetes inadequately controlled on metformin alone in Indian clinical settings. All patients successfully completed the treatment course without interruption, thus highlighting the sustained glycemic efficacy of the therapy.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.